ATR-04

The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches.

Azitra has initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline results by year-end 2025.

Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.

Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.

Azitra's ATR-04, a topical therapy for moderate to severe skin rash induced by EGFR inhibitors, has received FDA Fast Track designation.